Ceramides and Pseudoceramides: The Battle for Barrier Repair in Pharmacy Cosmetics
Pharmacy brands are launching lines with plant-derived phytoceramides as an affordable alternative to animal ceramides, promising instant relief from tightness and record hydration without a lipid film.
Pharmacy cosmetics are experiencing what industry analysts call the "ceramide war." At first glance, this is a standard story about a "natural replacement": plant-based phytoceramides versus animal ceramides extracted from rice bran or, less publicly, from mammalian tissue extracts. But behind this binary opposition lies a much more complex picture—a tectonic shift in the supply chain, regulatory landscape, and the very concept of skin barrier protection.
The Essence: What's Really Happening
We are not witnessing a battle of "plants versus animals." We are witnessing a reshuffling of the ceramide market, valued at approximately $380 million USD annually, with growth rates estimated between 8% and 11% per year. The stakes are high, and the debate is not about ethics but about supply stability, price, and, critically, the chemical identity of the molecules.
True ceramides are sphingolipids composed of a sphingoid base and a fatty acid linked by an amide bond. In the human stratum corneum, they form lamellar bilayers and account for up to 50% of the intercellular matrix. Their function is not just "hydration" but creating a waterproof barrier that allows just enough water to pass through so the skin does not dry out.
Animal ceramides used in cosmetics are typically ceramides types I, II, III, and IV, extracted from bovine or ovine tissues. Chemically, they are identical to human ceramides, making them the gold standard. But they have three fatal problems. First, supply stability: any outbreak of a zoonotic disease can paralyze production. Second, regulatory pressure: the EU and Japan are tightening requirements for traceability of animal-derived raw materials, increasing compliance costs. Third, ethical demand: even the pharmacy audience, traditionally focused on efficacy rather than ideology, is starting to ask about ingredient origins.
Enter phytoceramides—molecules isolated from plant sources: wheat, rice, soy. Their main advantage is not that they are "plant-based" but that they are cheaper and more stable in supply. As of May 2026 contract prices, 1 kg of pharmacopoeia-grade animal ceramides costs between $1,200 and $1,800 USD. Phytoceramides from rice bran cost between $400 and $700 USD per kg. A 2-3 times difference.
But there is a nuance: chemically, phytoceramides are not ceramides. Plants do not have sphingolipids in the same form as animals. What the industry calls "phytoceramides" are typically glycosylceramides: a sphingoid base linked not to a free fatty acid but to a sugar residue. In the human stratum corneum, glycosylceramides do not work directly—they must first be enzymatically cleaved to release the active ceramide component. But in a cream, they do not undergo this pathway. They form an occlusive film on the skin surface that mimics barrier function but does not restore the native lamellar structure.
Timeline and Context
Until 2023, the ceramide market was relatively calm. Key players included Evonik (Germany) with its biotechnological ceramides based on yeast fermentation, and Takasago International (Japan), holding patents on ceramide extraction from rice bran. The pricing niche was established: biotechnological and animal ceramides occupied the premium segment, while plant glycosylceramides were in mass market.
The turning point was 2024. First, updated recommendations from the European Medicines Agency (EMA) on the use of animal-derived substances in dermatological preparations significantly raised the bar for documentation and testing. Second, two major outbreaks of bovine disease in Brazil temporarily disrupted animal ceramide supplies. Third, major pharmacy brands—CeraVe, La Roche-Posay, Bioderma—began internal supply chain audits for ESG compliance.
By early 2026, almost all major players announced a strategic shift to "vegan ceramides" within 2-3 years. But here lies a critical fork: some brands are genuinely investing in biotechnological ceramides obtained through fermentation (chemically identical to human ceramides), while others are repackaging cheap rice glycosylceramides in the marketing guise of "plant-based ceramides."
Who Wins and Who Loses
Winners are biotech companies with fermentation-based ceramide synthesis technology. Evonik invested over €150 million in expanding production in Slovakia and plans to double capacity by 2027. Their product—ceramide NP (Ceramide 3), synthesized by yeast—is an exact chemical copy of human ceramide and bypasses all regulatory restrictions on animal raw materials.
Winners are rice mills and rice bran producers. Bran, once considered a byproduct, has suddenly become a valuable cosmetic ingredient. Procurement prices for cosmetic-grade rice bran have risen by 35% over two years.
Losers are producers of animal raw materials for cosmetics. These are small, often private companies that have worked with the meat processing industry for decades. For them, the "ceramide transition" means losing up to 60% of revenue in the next five years.
Losers are dermatologists and pharmacists who have built protocols around animal ceramides for years. They will have to retrain and rewrite recommendations because replacing animal ceramide with glycosylceramide is not clinically equivalent.
What the Media Isn't Saying
First fact: glycosylceramides create a "false barrier" effect on the skin. They provide instant relief from tightness, which marketers love, but do not participate in the physiological restoration of the lipid matrix. The skin feels hydrated, but the barrier function is not restored, making it vulnerable in the long term. A clinical study published in the Journal of Cosmetic Dermatology in January 2026 showed that after four weeks of using a cream with glycosylceramides, transepidermal water loss decreased by 18%, while a cream with human-identical ceramides showed a 34% reduction. The difference is twofold, but the packaging looks the same, and the consumer does not see these numbers.
Second fact: the stability of plant glycosylceramides in formulations is a serious issue. They are prone to oxidation and hydrolysis, requiring the addition of antioxidants and chelators. As a result, a "natural" product may contain more synthetic stabilizers than a traditional cream with animal ceramides.
Third, the most non-obvious insider point: "phytoceramides" as a legal loophole. The term "phytoceramides" is not regulated by the FDA or EMA. This allows brands to use it for labeling products that contain not a single molecule that is chemically a ceramide. Essentially, consumers buy a cream with glycosylceramides, thinking they are getting a full replacement for barrier lipids. When this fact becomes widely known—and it's only a matter of time—a scandal comparable to "clean" beauty marketing will erupt.
Forecast: Next 30 Days and 90 Days
In the next 30 days, we will see a cascade of new "vegan" lines from pharmacy brands. La Roche-Posay will release an updated version of Toleriane with "phytoceramides," Bioderma will launch Sensibio Ceramide. Pharmacy shelves will fill with products bearing green "vegan" and "plant-based ceramides" labels. Consumer confusion will begin: buyers will not be able to distinguish biotechnological ceramide from glycosylceramide.
In the next 90 days, by August 2026, the situation will escalate. First, a major dermatologist with a large social media following (likely Dr. Dray or Dr. Sameer Gupta) will publish an analysis clearly distinguishing "real" ceramides from "pseudoceramides." This will cause panic among consumers and a wave of returns. Second, regulators—first European, then the FDA—will issue preliminary guidelines on labeling ceramide-containing cosmetics, requiring the chemical nature of the ingredient to be specified, not just "ceramide" or "phytoceramide."
The most long-term forecast: by the end of 2026, the market will split into three distinct segments. Premium: biotechnological ceramides, chemically identical to human ceramides, with clinically proven barrier repair efficacy, cream price $35-55 USD per 50 ml. Mid-tier: a blend of glycosylceramides with a small addition of biotechnological ceramides, price $18-30 USD. Mass market: pure glycosylceramides that provide a temporary feeling of hydration but do not repair the barrier, price $8-15 USD. And the most interesting part: visually, in texture and initial skin feel, these three categories will be indistinguishable. The difference will show after 3-4 weeks of use, when the barrier either recovers or remains just as vulnerable.
The "ceramide war" is the first case in the history of pharmacy cosmetics where the marketing trend toward "plant-based" directly conflicts with clinical efficacy. And this conflict will be resolved not in laboratories but in courts and on the pages of regulatory documents. When the dust settles, it will turn out that the only way to get a true ceramide from plants is to feed them to yeast and wait for them to synthesize the desired molecule. But that is no longer "phyto" but "bio," and that is a whole different story.
— Editorial Team
